Vanda Pharmaceuticals (VM4) Stock Overview
A biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
VM4 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Vanda Pharmaceuticals Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$6.90 |
| 52 Week High | US$7.60 |
| 52 Week Low | US$3.46 |
| Beta | 0.61 |
| 1 Month Change | -1.43% |
| 3 Month Change | 51.98% |
| 1 Year Change | 46.81% |
| 3 Year Change | 18.97% |
| 5 Year Change | -53.69% |
| Change since IPO | -10.39% |
Recent News & Updates
Recent updates
Shareholder Returns
| VM4 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -2.1% | -3.8% | -5.4% |
| 1Y | 46.8% | 0.6% | -2.4% |
Return vs Industry: VM4 exceeded the German Biotechs industry which returned 6.7% over the past year.
Return vs Market: VM4 exceeded the German Market which returned 0.7% over the past year.
Price Volatility
| VM4 volatility | |
|---|---|
| VM4 Average Weekly Movement | 15.4% |
| Biotechs Industry Average Movement | 9.7% |
| Market Average Movement | 5.6% |
| 10% most volatile stocks in DE Market | 14.6% |
| 10% least volatile stocks in DE Market | 2.7% |
Stable Share Price: VM4's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: VM4's weekly volatility has increased from 10% to 15% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 533 | Mihael Polymeropoulos | www.vandapharma.com |
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s commercial portfolio includes Fanapt for the acute treatment of manic or mixed episodes associated with bipolar I disorder and the treatment of schizophrenia; HETLIOZ to treat non-24-hour sleep-wake disorders and nighttime sleep disturbances; PONVORY to treat relapsing forms of multiple sclerosis; and NEREUSTM for preventing vomiting induced by motion. It also develops Fanapt (iloperidone), a long acting injectable (LAI) formulation for the treatment of schizophrenia and hypertension; BysantiTM (milsaperidone), for the acute treatment of manic or mixed episodes associated with bipolar I disorder, and for the treatment of schizophrenia and major depressive disorder; HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, pediatric insomnia, delayed sleep phase disorder, and pediatric Non-24; PONVORY (ponesimod) to treat psoriasis and ulcerative colitis; and NEREUSTM (tradipitant) for prevention of vomiting induced by GLP-1 receptor agonists, as well as treatment of gastroparesis and atopic dermatitis.
Vanda Pharmaceuticals Inc. Fundamentals Summary
| VM4 fundamental statistics | |
|---|---|
| Market cap | €418.67m |
| Earnings (TTM) | -€190.45m |
| Revenue (TTM) | €186.67m |
Is VM4 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VM4 income statement (TTM) | |
|---|---|
| Revenue | US$216.11m |
| Cost of Revenue | US$13.04m |
| Gross Profit | US$203.06m |
| Other Expenses | US$423.54m |
| Earnings | -US$220.47m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.73 |
| Gross Margin | 93.96% |
| Net Profit Margin | -102.02% |
| Debt/Equity Ratio | 0% |
How did VM4 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/03/05 21:54 |
| End of Day Share Price | 2026/03/05 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Vanda Pharmaceuticals Inc. is covered by 16 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | Argus Research Company |
| Olivia Brayer | BofA Global Research |
| Madison Wynne El-Saadi | B. Riley Securities, Inc. |